What this study is
Determine the utility of biomarkers measured in blood and body fluid (stool, saliva, tracheal aspirate) when combined with clinical data, for predicting sepsis phenotypes that are associated with poor clinical outcomes. We hypothesize that resistin is a biomarker which provides critical prognostic information when used in conjunction with standard clinical data, in patients with sepsis and septic shock.
Study details
- Official title
- Diagnostic and Prognostic Biomarkers to Elucidate Sepsis Endotypes
- Sponsor
- Milton S. Hershey Medical Center
- Conditions
- Sepsis
- Enrolling
- 200 people
- Starts
- 2020-08-06
- Est. completion
- 2028-06-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Adults (age ≥ 18 )
- Gender: male or female
- Cognitively intact or impaired patients, given that sepsis may cause a certain degree of cognitive dysfunction in patients. All patients in the control group (no sepsis) will be cognitively intact
- Clinical suspicion for sepsis (except for control/comparison group for whom infection is NOT a current concern)
You can't join if
- Patients with hematologic malignancies
- Pregnant women
- Patient/surrogate is not fluent in English and no translation services are available
- Long-term immunosuppressive therapy
- Prisoner
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openMilton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Study team
Sponsor
Milton S. Hershey Medical Center
Study ID 7188
Principal investigator
Anthony Bonavia, M.D.
Milton S. Hershey Medical Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.